Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia

European Journal of Haematology

Volumn 76, Issue 5, 2006, Pages 444-446

  Moore, James C ^a   Dennehey, Carolyn F ^a   Anavim, Arash ^a   Kong, Kevin M ^a   Tiong Ong, S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b 116 Sprague Hall ^*  (United States)

Author keywords

Chronic myelogenous leukaemia; Imatinib; Joint effusions

Indexed keywords

HYDROXYUREA; IMATINIB; INTERFERON; LIDOCAINE; METHYLPREDNISOLONE ACETATE; PREDNISONE;

ADVANCED CANCER; AGED; ARTICLE; ASPIRATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FLUID RETENTION; HUMAN; JOINT EFFUSION; MYALGIA; NAUSEA; PEPTOSTREPTOCOCCUS; PERIORBITAL EDEMA; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; FEMALE; FOLLOW-UP STUDIES; HIP JOINT; HUMANS; JOINT DISEASES; KNEE JOINT; LEUKEMIA, MYELOID, CHRONIC; MAGNETIC RESONANCE IMAGING; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 33645724480     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00649.x     Document Type: Article

References (11)

1. B hatia R H oltz M N iu N G ray R et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment Blood 2003 101 4701 4707
2. M erante S O rlandi E B ernasconi P C alatroni S B oni M L azzarino M Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation Haematologica 2005 90 979 981
3. G raham SM J orgensen HG A llan E et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood 2002 99 319 325
4. L ahaye T R iehm B B erger U et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up Cancer 2005 103 1659 1669
5. O 'Brien SG G uilhot F L arson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 2003 348 994 1004
6. G rinspoon S C arr A Cardiovascular risk and body-fat abnormalities in HIV-infected adults N Engl J Med 2005 352 48 62
7. L ichtenstein KA W ard DJ M oorman AC et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population Aids 2001 15 1389 1398
8. D eininger MW O 'Brien SG F ord JM D ruker BJ Practical management of patients with chronic myeloid leukemia receiving imatinib J Clin Oncol 2003 21 1637 1647
9. B reccia M D 'Elia GM D 'Andrea M L atagliata R A limena G Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib Eur J Haematol 2005 74 89 90
10. E bnoether M S tentoft J F ord J B uhl L G ratwohl A Cerebral oedema as a possible complication of treatment with imatinib Lancet 2002 359 1751 1752
11. P ietras K O stman A S joquist M et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors Cancer Res 2001 61 2929 2934